Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmala Biotech HoldingsXCNQ:MDMA -1.96%38 Days Inventory is 259.07 as of May. 2026, which is 83% below its 10-year median of 1,539.99. GuruFocus rates XCNQ:MDMA with a GF Score™ of 38/100 and a GF Value™ of C$0.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 640 Biotechnology companies, Pharmala Biotech Holdings ranks worse than 85% on this metric.
The historical rank and industry rank for Pharmala Biotech Holdings's Days Inventory or its related term are showing as below:
XCNQ:MDMA'
s Days Inventory Range Over the Past 10 Years
Min: 556.86 Med: 1539.99 Max: 21170
Current: 577.94
During the past 5 years, Pharmala Biotech Holdings's highest Days Inventory was 21170.00. The lowest was 556.86. And the median was 1539.99.
XCNQ:MDMA's Days Inventory is ranked worse than 85% of 640
companies
in the Biotechnology industry
Industry Median: 183.115
vs XCNQ:MDMA: 577.94
Pharmala Biotech Holdings's Days Inventory
declined
from May. 2025 (3,680.42) to May. 2026 (259.07).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharmala Biotech Holdings's Inventory Turnover for the
three
months ended in May. 2026 was 0.35.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharmala Biotech Holdings's Inventory-to-Revenue for the
three
months ended in May. 2026 was 0.96.
Pharmala Biotech Holdings (XCNQ:MDMA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharmala Biotech Holdings's Inventory Turnover for the
three
months ended in May. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharmala Biotech Holdings's Inventory to Revenue for the
three
months ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Pharmala Biotech Holdings Days Inventory Related Terms
Pharmala Biotech Holdings Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:MDMA vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Pharmala Biotech Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmala Biotech Holdings Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where Pharmala Biotech Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmala Biotech Holdings (XCNQ:MDMA) has a Days Inventory of 259.07 as of May. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pharmala Biotech Holdings and its competitors. This is 83% below median its historical median of 1,539.99. Over the past decade, Pharmala Biotech Holdings' Days Inventory has ranged from 556.86 to 21,170.00. According to the industry distribution chart, Pharmala Biotech Holdings ranks #544 out of 640 companies in the Biotechnology industry, placing it in the top 85%.
Is Pharmala Biotech Holdings' Days Inventory too high?
Pharmala Biotech Holdings' current Days Inventory of 259.07 is 83% below median its 10-year median of 1,539.99. Over the past 10 years, this metric has ranged from a low of 556.86 to a high of 21,170.00. The Biotechnology industry median Days Inventory is 183.12. Pharmala Biotech Holdings' value of 259.07 is 41.5% above this industry median. Based on the distribution chart, Pharmala Biotech Holdings ranks #544 out of 640 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmala Biotech Holdings has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmala Biotech Holdings ranks #544 out of 640 companies for Days Inventory. This places Pharmala Biotech Holdings in the lower half of its industry. The industry median Days Inventory is 183.12. Pharmala Biotech Holdings' value of 259.07 is 41.5% above this benchmark. Historically, Pharmala Biotech Holdings' own Days Inventory has ranged from 556.86 to 21,170.00 over the past decade. While the company's 10-year median is 1,539.99 vs. the industry median of 183.12, Pharmala Biotech Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.12, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmala Biotech Holdings's current Days Inventory of 259.07 is 41.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pharmala Biotech Holdings and its competitors. For the Biotechnology industry, the median Days Inventory is 183.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmala Biotech Holdings's current Days Inventory is 259.07, which is 83% below median its own 10-year median of 1,539.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (XCNQ:MDMA) is currently considered Fairly Valued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.25 — trading right at its estimated fair value. The current Days Inventory is 259.07, which is 83% below median its 10-year median of 1,539.99 and 41.5% above the Biotechnology industry median of 183.12. Pharmala Biotech Holdings' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Pharmala Biotech Holdings (XCNQ:MDMA), the current Days Inventory is 259.07 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmala Biotech Holdings (XCNQ:MDMA) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued.
The current stock price of C$0.25 is trading 0% below its estimated GF Value™ of C$0.25.
GuruFocus considers Pharmala Biotech Holdings to be Fairly Valued.
Key valuation signals for XCNQ:MDMA:
Days Inventory: 259.07 (83% below median its 10-year median of 1,539.99)
GF Value™: C$0.25 vs. price of C$0.25 (0% below fair value)
Industry Position: 41.5% above the Biotechnology median (#544 of 640)
No single metric tells the full story. See the XCNQ:MDMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
38GF Score
Get the complete analysis for XCNQ:MDMA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:MDMA has been successfully added to your 
